ArticleMedicine2026
Clinical and genotypic characteristics of 19 children with STXBP1-encephalopathy.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
To systematically summarize the clinical phenotypes, treatment responses, prognosis, and genetic characteristics of STXBP1-encephalopathy in Chinese pediatric patients, and to explore the clinical value of genetic testing in this disease. We retrospectively analyzed the clinical data, gene variant information, and treatment outcomes of 19 children with STXBP1-encephalopathy admitted to the Department of Pediatrics, Second Affiliated Hospital of Zhejiang University, between January 2020 and January 2024. Whole-exome sequencing was performed for genetic diagnosis, and Sanger sequencing was used to verify variants and confirm their parental origin. Pathogenicity of variants was classified according to the American College of Medical Genetics and Genomics guidelines. STXBP1-encephalopathy showed early onset, with 15 cases (78.9%) occurring within the 1st month of life. Five patients were diagnosed with Ohtahara syndrome, 5 with West syndrome, and 9 with unclassifiable early-onset epileptic encephalopathy. All patients had abnormal electro-encephalogram findings, mainly burst suppression (68.4%) and hypsarrhythmia (63.2%). Among the 19 patients, 1 achieved seizure freedom and discontinued antiepileptic drugs, and 4 achieved seizure control with levetiracetam. A total of 18 de novo pathogenic/likely pathogenic variants in STXBP1 were identified, including 7 novel variants: c.326-3(IVS5)delC, c.656del(p.Met219Argfs*13), c.746-747del(p.F249fs*6), c.798T > G(p.Y266*), c.1155delC(p.D385fs), c.1249G > A(p.G417S), and c.1250-2A > G. STXBP1 pathogenic variants are an important cause of early-onset developmental epileptic encephalopathy in Chinese children. Genetic testing is crucial for early diagnosis of STXBP1-encephalopathy. Levetiracetam shows good efficacy in controlling seizures in these patients, and early use is recommended. The 7 novel variants identified in this study expand the STXBP1 mutation spectrum.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.